As the world tries to come back to normal from the COVID-19 pandemic, although some vaccines have already received Emergency Use Authorizations (EUAs), including those developed by Pfizer and Moderna, many companies and organizations continue to run clinical trials to find vaccines and therapeutics for COVID-19. GlobalData continues to gather and analyze those COVID-19 clinical trials since the beginning of the pandemic.

Overall, the number of COVID-19 clinical trials continues to increase into 2021. As of March 8, 2021, clinical trials in the US continue to greatly outnumber those in other countries. Currently, the US has 823 clinical trials, almost double that of India, which is second with 491 clinical trials. China, Iran, and Spain round out the top five, all of which have more than 200 COVID-19 clinical trials. China has had the slowest increase, which can be seen in Figure 1 below. The number of clinical trials for China slowly increased from 318 to 488 over the course of the pandemic, an almost flat line compared to the US and India.

With the number of COVID-19 clinical trials continuing to rise all over the world, analysis will continue to clarify which countries will have the most trials. While the US will continue to dominate, India expects to continue to increase their number of clinical trials, as seen with the steep increase in the graph below.